![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
PERSPECTIVES IN PHARMACOLOGY
Temple University School of Medicine, Philadelphia, Pennsylvania
Drugs given in combination may produce effects that are greater than or less than the effect predicted from their individual potencies. The historical basis for predicting the effect of a combination is based on the concept of dose equivalence; i.e., an equally effective dose (a) of one will add to the dose (b) of the other in the combination situation. For drugs with a constant relative potency, this leads to linear additive isoboles (a-b curves of constant effect), whereas a varying potency ratio produces nonlinear additive isoboles. Determination of the additive isobole is a necessary procedure for assessing both synergistic and antagonistic interactions of the combination. This review discusses both variable and constant relative potency situations and provides the mathematical formulas needed to distinguish these cases.
Address correspondence to: Dr. Ronald J. Tallarida, Temple University School of Medicine, 3420 N. Broad Street, Philadelphia, PA 19140. E-mail: Ronald.tallarida{at}temple.edu
This article has been cited by other articles:
|
|
 |
|
  K. A. Zarember, A. R. Cruz, C.-Y. Huang, and J. I. Gallin Antifungal Activities of Natural and Synthetic Iron Chelators Alone and in Combination with Azole and Polyene Antibiotics against Aspergillus fumigatus Antimicrob. Agents Chemother., June 1, 2009; 53(6): 2654 - 2656. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Stergiopoulou, J. Meletiadis, T. Sein, P. Papaioannidou, I. Tsiouris, E. Roilides, and T. J. Walsh Isobolographic Analysis of Pharmacodynamic Interactions between Antifungal Agents and Ciprofloxacin against Candida albicans and Aspergillus fumigatus Antimicrob. Agents Chemother., June 1, 2008; 52(6): 2196 - 2204. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. S. Braverman, R. J. Tallarida, and M. R. Ruggieri Sr. The Use of Occupation Isoboles for Analysis of a Response Mediated by Two Receptors: M2 and M3 Muscarinic Receptor Subtype-Induced Mouse Stomach Contractions J. Pharmacol. Exp. Ther., June 1, 2008; 325(3): 954 - 960. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Vazquez-Martin, C. Oliveras-Ferraros, R. Colomer, J. Brunet, and J. A. Menendez Low-scale phosphoproteome analyses identify the mTOR effector p70 S6 kinase 1 as a specific biomarker of the dual-HER1/HER2 tyrosine kinase inhibitor lapatinib (Tykerb(R)) in human breast carcinoma cells Ann. Onc., June 1, 2008; 19(6): 1097 - 1109. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. J. Ward, T. W. Lefever, C. Jackson, R. J. Tallarida, and E. A. Walker Effects of a Cannabinoid1 Receptor Antagonist and Serotonin2C Receptor Agonist Alone and in Combination on Motivation for Palatable Food: A Dose-Addition Analysis Study in Mice J. Pharmacol. Exp. Ther., May 1, 2008; 325(2): 567 - 576. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Markovic, M. Vatish, M. Gu, D. Slater, R. Newton, H. Lehnert, and D. K. Grammatopoulos The Onset of Labor Alters Corticotropin-Releasing Hormone Type 1 Receptor Variant Expression in Human Myometrium: Putative Role of Interleukin-1{beta} Endocrinology, July 1, 2007; 148(7): 3205 - 3213. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Punn, M. A. Levine, and D. K. Grammatopoulos Identification of Signaling Molecules Mediating Corticotropin-Releasing Hormone-R1{alpha}-Mitogen-Activated Protein Kinase (MAPK) Interactions: The Critical Role of Phosphatidylinositol 3-Kinase in Regulating ERK1/2 But Not p38 MAPK Activation Mol. Endocrinol., December 1, 2006; 20(12): 3179 - 3195. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
